This study aims to investigate the use of palm olein as the oil phase for betamethasone 17-valerate (BV) emulsions. The physicochemical properties of the formulations were characterized. In vitro drug release study was performed with the Hanson Vertical Diffusion Cell System; the samples were quantified with HPLC and the results were compared with commercial products. Optimized emulsion formulations were subjected to stability studies for 3 months at temperatures of 4, 25, and 40°C; the betamethasone 17-valerate content was analyzed using HPLC. The formulations produced mean particle size of 2-4 μm, viscosities of 50-250 mPa.s, and zeta potential between −45 and −68 mV. The rheological analyses showed that the emulsions exhibited pseudoplastic and viscoelastic behavior. The in vitro release of BV from palm olein emulsion through cellulose acetate was 4.5 times higher than that of commercial products and more BV molecules deposited in rat skin. Less than 4% of the drug was degraded in the formulations during the 3-month period when they were subjected to the three different temperatures. These findings indicate that palm olein-in-water emulsion can be an alternative vehicle for topical drug delivery system with superior permeability.
INTRODUCTION
Topical glucocorticoids are the most frequently used drugs in dermatological practices. Among them, betamethasone 17-valerate is a potent, long-acting glucocorticoid receptor agonist which is highly recommended as a vasoconstrictive, anti-inflammatory, and antiproliferative agent for the treatment of skin diseases such as inflammatory dermatoses, atopic and infantile eczemas, seborrheic dermatitis, and mild to moderate psoriasis. Due to poor oral bioavailability, it is most frequently prescribed as topical preparations such as lotions and creams, which are basically emulsions (1) .
An emulsion is a colloidal dispersion in which two or more immiscible liquids are homogenized and stabilized by the addition of one or more surfactants. Emulsions can be generally classified into oil-in-water (o/w) emulsion, water-inoil (w/o) emulsion, oil-in-water-in-oil (o/w/o) emulsion, or water-in-oil-in-water (w/o/w) emulsion. Conventionally, the petroleum-based mineral oils such as liquid paraffin and white soft paraffin have been used as the oil phase of emulsions (2, 3) . The commercially available topical oil-in-water creams of betamethasone 17-valerate are prepared using mineral oils as the oil phase with pH range of about 4.5 to 6.5 (4) . Environmental considerations have led to the search for renewable, biodegradable, and eco-friendly alternatives such as vegetable oils, which are inexhaustible and contain natural constituents with desirable properties (5) .
Among the extensively used vegetable oils is palm olein, which is the liquid part of fractionated palm oil. Palm olein is naturally blessed with antioxidants such as tocotrienols and phospholipids which act as a surface-active agent. This adds up the uniqueness of palm olein as the oil phase in an emulsion system (6) . Moreover, these tocotrienols and carotenoids present in palm olein also contribute to health benefits such as cardioprotection, neuroprotection, and skin nutrition (7) . Malaysia is the world's leading supplier of palm oil and its esters which are extracted from the fruit of Elaeis guineensis. Although most of the palm oil is used in the food industry, the application of palm oil in the pharmaceutical field has not been widely investigated (6) .
Thus, this study aimed to establish and investigate the use of palm olein emulsion as an alternative vehicle for topical delivery of betamethasone 17-valerate, a lipophilic drug. The emulsions were prepared using Span 20 and Tween 20 as surfactants, Carbopol 940 as thickener, sodium methylparaben, sodium propylparaben and chlorocresol as preservatives, propylene glycol as solubilizer, and distilled water as the aqueous phase. The formulations were characterized for particle size distribution, viscosity, rheology, and zeta potential. Evaluation on drug release with three different viscosities was further performed with the Hanson Vertical Diffusion Cell System using cellulose acetate as well as rat skin as membranes, and the samples were quantified with HPLC. The results were compared with those of three commercial products. The emulsions were stored in two containers and closure systems as per ICH guideline and further subjected to stability studies for 3 months at three different temperatures (4, 25 , and 40°C); degradation of betamethasone 17-valerate in the formulations was analyzed using HPLC.
MATERIALS AND METHODS

Materials
Refined, bleached, and deodorized palm olein was supplied by Plant Succeed Engineering, Malaysia. Span 20, Tween 20, propylene glycol, HPLC grade methanol, and glacial acetic acid were purchased from MERCK, Germany. Industrial grade Carbopol 940 was supplied by Acros Organics, USA. Sodium methylparaben and sodium propylparaben were obtained as a gift from Fikrah Engineering Sdn. Bhd., Malaysia. Chlorocresol and pharmaceutical grade betamethasone 17-valerate were provided by Apollo Healthcare Inc., China. The HPLC grade acetonitrile (Thermo Scientific) was purchased from Fisher Scientific (M) Sdn. Bhd. The reference standard with 99.9% purity, norethisterone (Sigma-Aldrich), was provided by Nano Life Quest Sdn. Bhd. Transparent plastic containers (capacity 100 g, length 3.2 in., diameter 1.8 in.) with white screwed caps were purchased from a local pharmacy outlet (Kuantan, Malaysia). The commercial (reference) products were purchased from a local pharmacy outlet in Kuantan, Malaysia. The selections were based on the strength of the active ingredient, types of preservatives, and viscosities.
Solubility Measurement of Betamethasone 17-Valerate
Solubility measurements of the drug in palm olein, distilled water, Span 20/Tween 20 mixture, oil and surfactants mixed phase, and receptor medium were performed by dissolving excess of the drug in 2 mL of the vehicle components and receptor medium contained in small vials. The vials were wrapped with aluminum foil to prevent drug decomposition and stirred for 3 days at 25 ± 0.5°C using an incubator shaker (Innova®4000, New Brunswick Scientific, USA). After 3 days, the drug fractions dissolved in oil phase, surfactants, and oil and surfactants mixed phase were extracted with equal amount of methanol by centrifuging at 5000 rpm for 20 min at 4°C using a centrifuge (32 R Universal, Germany) (8) . Immediately after centrifuging, the supernatant was collected, filtered through 0.45 μm membrane filter, and further analyzed with U-1900 UV/ Visible Spectrophotometer (HITACHI, Japan) at 254 nm for drug content (9) .
Formulation of Betamethasone 17-Valerate Emulsions
Preparation of 1% (w/w) Carbopol 940 Solution
Carbopol 940 powder 2 g was dispersed into 160 g of distilled water in a beaker and stirred vigorously with a mechanical overhead stirrer (Ika Labortechnik, RW20.n, Germany) for 1 h at room temperature. Then, 2 mL of triethanolamine (MERCK, Germany) was carefully dropped into the dispersion with gentle stirring. Finally, the remaining distilled water was added to make 200 g followed by gentle stirring for 30 min (10, 11) . The pH of the gel was found to be 6.8 when measured using a portable pH meter (Hanna H1991001, UK).
Preparation of Betamethasone 17-Valerate Slurry
At room temperature, 0.36 g of betamethasone 17-valerate, 0.6 g of sodium methylparaben, 0.18 g of sodium propylparaben, and 1.2 g of chlorocresol were dissolved in 60 g of propylene glycol in a beaker (12) . The same slurry without the addition was prepared for control emulsions.
Preparation of 20% (w/w) Palm Olein-in-Water Emulsions
Thirty grams of Span 20 and Tween 20 mixture at effective HLB 10 was added to a beaker containing 120 g palm olein. The mixture was then warmed on a hot plate to 60°C with gentle stirring to assist the mixing of oil and surfactant. When the oil and surfactants were totally mixed, the beaker was removed from the hot plate and distilled water was gradually added to the mixed oil phase. The mixture was homogenized at 8000 rpm for 20 min at room temperature (6) . The homogenizer used was Ultra-Turrax® T25 Basic homogenizer (Ika Labortechnik, Germany), equipped with a dispersing head S25N-25GM consisting of a rotor (diameter 17 mm) that rotates within a stationary stator (13) .
Preparation of Control and Test Emulsions
Three test emulsions were prepared by adding betamethasone 17-valerate into the emulsion with gentle stirring. Varied amount of 1% (w/w) Carbopol 940 solution was added to the control and test emulsions as shown in Table I to obtain the desired viscosities. The emulsions were then stirred thoroughly with a mechanical overhead stirrer for 10 min (6).
Characterization
The oil droplet size of the emulsions was determined using a Laser Particle Size Analyzer (BT-9300H, China). Zeta Sizer (ZEN2600, Malvern Instruments, UK) was used to obtain the zeta potential of the emulsions. Samples were diluted with distilled water.
The rheological properties were measured using Haake MARS Rheometer (Thermal Analysis, Germany). Data analysis was done using Haake RheoWin 3.61.0000 software. The spindle used for all the experiments was PP35 Ti with 35 mm diameter. Up and down rotational controlled rate (CR) ramp test, rotational control stress (CS) ramp test, oscillation stress sweep test, and oscillation frequency sweep test were performed.
In Vitro Drug Diffusion Studies
The in vitro drug diffusion studies were performed using a static Hanson Vertical Diffusion Cell System (PolyScience, USA) containing six cells with a receptor compartment volume of 7 mL and an effective diffusion area of 1.8 cm 2 . The experiments were conducted using both synthetic and biological membranes. The aim of using a synthetic membrane which supports diffusion of the drug from vehicle to receptor medium was to evaluate the ability of palm oleinin-water emulsion in releasing the drug, while the biological membrane serves as a barrier for drug diffusion that mimics human skin. An ethanol to phosphate buffer solution (PBS) ratio of 40:60 (v/v) was used as receptor medium. This is the best medium to study the diffusion of betamethasone 17-valerate for this work (Table II) . The temperature of the medium in the jacketed diffusion cell was controlled to 32 ± 0.5°C using a circulating water bath (14, 15) .
In Vitro Drug Release Studies Using Synthetic Membrane
Cellulose acetate membranes (diameter 25 mm, pore size 0.45 μm, and thickness 110 μm) were soaked in a beaker containing receptor medium for 30 min (16) at 37.5°C to remove preservatives and plasticizers. They were carefully mounted on top of the respective cells. Test emulsions and commercial products (both 300 mg) were applied with a spatula on the central top of a membrane inside the dosage wafer cavity, and the cells were assembled as per equipment manual. The helix mixer and magnetic stirrer inside the receptor compartments of each cell were set at 300 rpm.
In Vitro Skin Permeation Studies Using Rat Skin
Full-thickness abdominal skins of male albino Wistar rats, weighing 80-120 g, were donated by the Animal Laboratory, Kulliyyah of Pharmacy, IIUM. The hairs on the outer skin surface were removed with dissecting scissors, brought as closest as possible to the skin without any harm to the stratum corneum. The subcutaneous tissues were surgically removed, and the dermis side was wiped with 100% isopropyl alcohol to remove the adhering fatty layer and connective tissue layer. The skin was washed with PBS, wrapped in aluminum foil, and stored in a deep freezer at −40°C until further use. On the day of the experiment, the skin samples were taken out from the deep freezer and thawed at room temperature. Prior to the test, the skin samples were equilibrated by soaking in 0.9 N NaCl solution for 30 min at 37.5°C. The experimental procedures for permeation studies were the same as mentioned in the synthetic membrane section. The skin samples were mounted over the diffusion cells in such a way that the dermis faced the receptor compartment while stratum corneum side faced the donor compartment.
All the experiments were carried out in triplicates for a duration of 6 h; 0.5 mL of the sample solution was withdrawn from the receptor compartment via the sampling port at 0.5, 1, 2, 4, and 6 h intervals. To maintain the sink condition, the receptor phase, once sampled, was immediately replenished with equal volume of fresh receptor medium. The concentrations of betamethasone 17-valerate in the sample solutions were quantified by HPLC.
Estimation of Drug Content in the Skin
Skin samples were removed from the apparatus and the formulations left on the skin were removed with a spatula, and the skins were washed with ultra-pure distilled water (17) and wiped with tissue paper (Kimwipe®, Kimberly-Clark, Roswell, Germany) to remove any trace amount of emulsion attached to the skin. After cleaning, the effective diffusion area of the skins (1.8 cm 2 ) was cut into small pieces and sonicated with 10 mL of methanol for 30 min to extract the drug retained in the skin. The suspension was centrifuged for 10 min at 4000 rpm. The supernatant liquid was separated, filtered through 0.45 μm nylon membrane filter, and analyzed by HPLC (8, 18) .
HPLC Analysis
For drug assay, a reversed-phased HPLC system (Model-1200 Compact LC; Agilent Technologies, USA) was used. Data acquisition was performed using ChemStation Software (Agilent Technologies, USA). The stationary phase used was Eclipse Plus C 18 analytical column (250 mm × 4.6 mm i.d. × 5 μm), secured with a guard column (KJ0-4282, Agilent Technologies, USA). The validated HPLC method was adopted from the official monograph for betamethasone 17-valerate stated in the United States Pharmacopoeia (USP, 2005) with minor modifications. The mobile phase was acetonitrile:HPLC grade water (65:35 v/v) and was isocratically delivered at a flow rate of 1.2 min/mL at 35°C. The injection volume was 10 μL and the detector wavelength was set at 254 nm.
Calculation of the Cumulative Amount Release
The total concentration of betamethasone 17-valerate in the receptor compartment was determined by multiplying the drug concentration (μg/mL) obtained from HPLC analysis with the total volume of the receptor medium. The cumulative amount of the drug released for each formulation was calculated with the following equation (16, 19) :
Where Q is the cumulative amount of betamethasone 17-valerate released per surface area of the membrane (μg/cm 2 ), C n is the concentration of betamethasone 17-valerate determined at the nth sampling interval (μg/mL), V is the volume of individual diffusion cell, ∑ n−1 i¼1 C i is the sum of the concentrations of betamethasone 17-valerate determined at sampling intervals 1 through n − 1 (μg/mL), S is the volume of the sampling aliquot (0.5 mL), and A is the surface area of the sample well (1.8 cm 2 ). The cumulative amount of drug release for each formulation (Q, μg/cm 2 ) was plotted as a function of time (t, h), and the flux at steady state (J ss , μg/cm 2 /h) was calculated from the slope of the linear portion of the curve. The enhancement ratio (ER flux ) was further calculated by dividing J ss of the test product by J ss of the reference product (1). The permeability coefficient (K p ) was obtained by dividing the flux by initial drug concentration (C o ) in the donor portion of the cell (8).
Skin Hydration Test
All experiments were performed in accordance with current ethical norms approved by the Institutional Animal Care and Use Committee (IACUC), Integrated Centre for Research Animal, Care & Use (ICRACU), International Islamic University Malaysia, approval no: IIUM / IACUC Approval / 2014 / (3) (9). Abdominal skins (1.8 cm 2 ) of six rats were shaved carefully and cleaned; 300 mg of freshly prepared test emulsions T1, T2, and T3 and commercial emulsions R1, R2, and R3 were applied gently on shaved skins of separate rats, and skin hydration tests were carried out using SkinLab Combo 1.03 (DermaLab® Series, Denmark). 
Photostability Study
A solution having 1 μg/mL concentration was prepared by dissolving betamethasone 17-valerate in glacial acetic acid >and methanol (1 in 1000) solution. The solution was transferred into 1.5-mL screw-capped HPLC vial and irradiated at 25°C using an ordinary fluorescent lamp (20) which emits 40 lm/W. The ICH guidelines recommended to use any light source similar to D65 emission standard which mimics outdoor daylight or near ultraviolet lamp. Ordinary fluorescent lamp has similar light emission pattern as D65 (21) . The distance of the sample from the light source (30 cm) was kept unchanged throughout the study period. The study was performed up to 7 h to confirm the drug degradation profile only. The sample was analyzed with HPLC at 0.
Stability Study
Fifty grams of test emulsion, T3 (Table I) , was packed inside a screw-capped transparent plastic container; a total of ten containers were prepared. The samples were further divided into four groups: initial, A, B, and C. The stability studies were carried out by storing A and B samples at 25 and at 4°C, respectively, for 3 months. C samples were kept inside a climate chamber (KBF 240, Binder, Germany) which maintains the temperature at 40°C with relative humidity (RH) 75% for a period of 3 months. The samples were withdrawn after each month of storage (i.e., 0, 1, 2, and 3 months) to assess any changes in properties and drug content.
Sample Preparation
Five-milliliter aliquot of the glacial acetic acid and methanol (1 in 1000) solution, 3 g of emulsion containing 3 mg of betamethasone 17-valerate (equivalent to 2.5 mg of betamethasone), and 10 mL of internal standard solution were transferred into a 50-mL beaker, and the mixture was heated on a water bath at 60°C. Once breaking of the emulsion was achieved, it was removed from the water bath and stirred vigorously with a magnetic stirrer for 20 min. The heating and stirring cycle was repeated for another two times as stated in the USP/NF (2005). The sample was transferred to a 15-mL centrifuge tube and placed in ice-methanol bath for 20 min. The tube was further centrifuged at 9000 rpm for 10 min at 4°C. The clear supernatant solution was collected in HPLC vial wrapped with aluminum foil, equilibrated to room temperature, and further analyzed for drug content with HPLC (22) .
Drug Content Analysis by HPLC
The validated HPLC method was adopted from the official monograph for betamethasone 17-valerate operating condition for the HPLC analyses were as mentioned in the in vitro drug release studies (BHPLC Analysis^section).
Estimation of Shelf-Life
The amount of decomposed drug and the percentage of unchanged drug were calculated. The logarithm of percentage (Log %) of undecomposed drug for each sample was also calculated, and the order of reaction was determined using the graphical method (23, 24) . The temperatures (°C) were converted into absolute temperatures (Kelvin), and the degradation rate constants (K) for each temperature were determined from the slopes of the graphs. Finally, the shelf-life (t 0.9 ) of the emulsions stored inside plastic containers was calculated from degradation rate constant at 25°C (K 25 ) using the following shelf-life equation for first-order reaction:
Statistical Analysis
The data were analyzed with MINITAB® Version 16.1.0 Statistical software (Minitab Inc., USA). One-way ANOVA (Turkey's test) was carried out with 0.05 significant level. The p value of 0.05 or less was considered statistically significant. All the experiments were conducted three times and the values were expressed as mean ± standard deviation.
RESULTS AND DISCUSSION
Two series of emulsions, namely control emulsions and test emulsions, were obtained.
Solubility of Betamethasone 17-Valerate
The highest amount of drug was detected in methanol, followed by receptor medium, oil and surfactant mixed phase, palm olein, surfactants mixture, and distilled water:methanol at 70:30 (v/v) in decreasing order (see Table II ).
Characterization
The emulsions with small droplet size are highly beneficial to minimize phase separation and for better permeation of the drug across the skin. The size of oil droplets in all emulsions remained unchanged up to 12 months. A slight increase in particle size with increasing concentration of Carbopol 940 is found in all emulsions. Oil The viscosities of the emulsions increased markedly with increasing concentration of Carbopol 940 which may be probably due to the characteristics of Carbopol 940 gel. Barry and Meyer (38) reported that the viscosity of the formulation varied exponentially with the concentration of Carbopol 940 used. The value of yield stress indicates the strength of H-bonding interaction between surfactant molecules adsorbed on the oil droplets and gelled network of Carbopol 940, while the network strength becomes stronger with a higher concentration of Carbopol 940 (25, 26) . Therefore, higher yield stress values are achieved in formulations prepared with higher concentrations of Carbopol 940 as shown in Table III .
All the emulsions possessed negatively charged zeta potential, and the values increased with increasing concentration of Carbopol 940. The negative charge arises from the surface charge of oil droplets and further increase in the presence of Carbopol 940. Negatively charged oil droplets repel each other preventing aggregation. Therefore, the higher the zeta potential, the stronger the repulsion and the more stable the system becomes (27) .
When dissolved in water or polar solvents, the carboxyl groups in the polymer backbone of Carbopol 940 ionize. The resulting ionized carboxylate groups are responsible for the formation of H-bonding interaction with surfactant molecules adsorbed on the oil droplets, and hence, this influences the overall charge carried by the oil droplet. Therefore, formulations with higher concentration of Carbopol 940 had higher negatively charged zeta potential values due to the presence of negatively charged carboxylate ions (27) .
Rheological Properties
From the shape of the curves (see Fig. 2 ), the viscosities of all emulsions decrease gradually with increasing shear rate. This pointed out the shear thinning behavior of the emulsions which is the characteristic of pseudoplastic materials. For emulsions with pseudoplastic nature, the viscosity should not drastically decrease with increasing shear rate (28) . Resistance to flow decreases as the Carbopol 940 gel network is broken (29) . Domination of either storage or loss modulus over one another within a particular frequency range will indicate whether the material appears to be elastic or viscous (30) . The storage modulus (G′) is dominated over the loss modulus (G″), describing that the emulsions are more elastic in nature within the linear viscoelastic region with tangent phase angle value of less than 1 (tan δ < 1) (31) (32) (33) . The elasticity of the emulsions increases with increasing Carbopol 940 concentration as both G′ and G″ increased exponentially with Carbopol 940 concentration (see Fig. 3 ).
Drug Permeation Studies
In Vitro Drug Release Using Cellulose Acetate Membrane Figure 4 illustrates the permeation profiles of all test and commercial samples. The cumulative amount of betamethasone 17-valerate released from the test and commercial samples across cellulose acetate membrane are presented in Table IV .
Although the test and commercial samples had the same drug concentration, the flux of betamethasone 17-valerate from T1 and T2 was 4.76 times and 2.7 times higher, respectively, than the commercial samples. The diffusion pattern of a particular compound through a particular type of membrane is significantly different from that of other compounds. These differences in release profiles are governed by the physicochemical properties of the vehicle in which the drug is dissolved and of the chosen membrane such as pore size, porosity, tortuosity and thickness, the affinity of the drug for the membrane, as well as compositions of donor and receptor compartments (34) .
The high lipophilicity of betamethasone 17-valerate suggests that the drug is dissolved in the oil phase of oil-in-water emulsion (1). Therefore, the particle size of the oil droplet can have a marked effect on drug diffusion across the membrane. The formulation having smaller particle size was found to have greater amount of drug release.
The increase in viscosity of a vehicle enhances the formulation stability by resisting the movement of oil globules. Further, the formulations having higher viscosity have more resistance against drug diffusion. This explains the greatest amount of betamethasone 17-valerate permeated from T1, which is least viscous compared to T2 and T3. A similar trend was also found in commercial samples. In general, test samples show higher permeation than commercial samples. This may be due to the difference in the type of excipients and the nature of palm olein. In test samples, betamethasone 17-valerate has affinity for the oily component, palm olein. When compared to the vehicle components (palm olein and distilled water), betamethasone has greater affinity for the receptor medium, ethanol:PBS (40:60 v/v), due to higher solubility of the drug in the latter. Hence, more drug molecules diffused into the receptor solution. On the other hand, the commercial samples included more oily additives such as white soft paraffin, cetomacrogol 1000, cetostearyl alcohol, and liquid paraffin (12) . Therefore, the highly lipophilic permeant has greater affinity for the oily vehicle rather than for the receptor solution, resulting in decreased drug permeation.
In general, hydrophilic compounds have greater affinity for hydrophilic membranes and vice versa (16) . Cellulose acetate is a hydrophilic membrane, while betamethasone 17-valerate is a hydrophobic compound. As a result, betamethasone 17-valerate has low affinity for cellulose acetate, and hence, a certain extent of diffusion into the receptor medium occurred.
In Vitro Skin Permeation Studies Using Rat Skin
Betamethasone 17-valerate deposited in the rat skin after 6 h, although no drug molecule was detected in the receptor medium. Table V demonstrates the amount of betamethasone 17-valerate retained in all skin layers after 6 h. The permeation of a drug intended for local therapeutic effect on the skin should be kept to a minimum so that the uptake of the drug into the systemic circulation is low enough to avoid undesirable systemic side effects (35) . Despite the clinical effectiveness in the treatment of psoriasis and inflammatory dermatoses, the use of betamethasone 17-valerate is limited due to the general systemic adverse effects of glucocorticoids, such as hypothalamic-pituitary-adrenal axis suppression, Cushing's syndrome, cataracts, and femoral head osteonecrosis (36) . One of the means to reduce the systemic adverse effects of topical steroids is to improve their retention into the skin without augmenting the amount permeated (1, 37) . The amount of drug deposited in the skin of the test samples was higher than that of commercial samples in all experiments. The highest amount of drug was significantly retained in the skin for T1, followed by T2, T3, R3, R1, and R2 in decreasing order. Thus, all test samples were better than commercial samples in minimizing systemic delivery. The higher drug permeation from the test samples into the skin resulted from better physicochemical properties of the test samples such as having smaller oil droplet size, lesser viscosity, and lesser oily component (lesser affinity of the drug for the vehicle). In addition, test samples have higher skin hydration than the commercial products (Table III) . Water is reported as a natural penetration enhancer, and the hydration of the skin layers by water contained in the vehicles will improve the skin penetration of the drug (38) .
Generally, the drug molecules should have considerably low molecular weight (<500 Da) and intermediate lipophilicity (log P = 1-3) to overcome the barrier function of the stratum corneum and to permeate into the skin (39) . Betamethasone 17-valerate has a molecular weight of 476.6 with log P value of 3.71. Hence, betamethasone 17-valerate is believed to permeate across the stratum corneum through the intercellular lipid compartment pathway in the Bbrick and mortar^model. Since the corneocytes in rat skin are anucleated, keratinized dead cells, they do not possess specialized proteins required for active or facilitated transport processes across the stratum corneum (40) . The mechanism of drug transport across the stratum corneum is through passive diffusion and obeys Fick's first law of diffusion (41) .
Betamethasone 17-valerate was biotransformed by the enzymes present in rat skin after it was absorbed into the skin layers. Similar findings were reported by Kubota et al. (18) and Ademola et al. (42) using human skin in both the in vivo studies and in the living skin equivalent (LSE) model. Figure 5 illustrates the presence of its biotransformed products in the skin samples after 6 h.
After penetration into the skin, betamethasone 17-valerate was initially isomerized to betamethasone 21-valerate (first degradation compound, FD) which subsequently was hydrolyzed into a more polar betamethasone (second degradation compound, SD) by the activity of cytochrome P-450 enzyme present in the rat skin (18, 43) . This biotransformation of betamethasone 17-valerate into betamethasone 21-valerate is desirable as more active drug could be transformed faster from the latter (42).
Skin Hydration Test
The skin treated with T1 which contained the least concentration of Carbopol 940 showed the highest skin moisture content (Table III) . As Carbopol 940 concentration increases, the level of moisture content decreases. Carbopol 940 swells in water to form a three-dimensional network to increase viscosity of the formulation. Increased concentration of Carbopol 940 decreased the number of water molecules which are required to hydrate the skin. The water content in rat skin treated with T1 is twice higher than that of R3. Aqueous-based emulsions are more desirable in the treatment of psoriasis and eczemas in which the skin is dry and itchy. When test samples are applied to the skin, palm olein acts as lubricant and emollient, Carbopol 940 gel acts as cooling agent, and the skin is greatly hydrated due to the high water content in the test samples.
Stability Studies
Characterization
There is no change in oil droplet size and pH at all storage conditions for the test samples for up to 3 months. This result suggests that the surfactant system comprising of Span 20 and Tween 20 is sufficient to maintain stability (Table VI) .
From Fig. 6 , it can be seen that there is no change in G′, G″, and tan δ of T3 emulsion stored at 25°C. However, decreased elasticity of emulsion was observed after the sample was stored for the second and third months. Both G′ and G″ values were found to decrease with increasing shear stress in T3 emulsion with crossover observed when the stress was higher than 10 Pa. The linear viscoelastic region (LVR) was observed in the range of 0.1-1.0 Pa.
Photodegradation Studies
Photodegradation was found to increase with longer exposure to light source. After 1 h of irradiation, the first degradation compound, which is betamethasone 21-valerate, was detected in the sample solution. This occurs as a result of rearrangement of 17-valerate ester to 21-valerate ester, followed by subsequent hydrolysis of the 21-valerate isomer into a second degradation compound, which is betamethasone, detected after 3 h. It can be seen that 20% of the drug was degraded within 7 h (see Table VII) .
A similar trend of drug degradation was seen in samples kept inside plastic containers. Betamethasone 17-valerate degraded gradually with increasing temperature during the period of study. The least degradation was at 4°C, while the highest amount of drug degraded at 40°C for all samples. This is due to sensitivity of betamethasone 17-valerate toward heat (20) . The reactions involved in the formation of degraded compounds are oxidation and ester group migration of betamethasone 17-valerate into betamethasone 21-valerate followed by hydrolysis of betamethasone 21-valerate into betamethasone alcohol (44) . When kept for 3 months at 40°C, less than 4% of the drug was degraded.
The order of drug degradation was further determined by plotting Log % of unchanged drug against time (Table VIII) . The plot indicated that the degradation followed a first-order reaction (see Fig. 7 ). The first-order degradation rate constant (K) per month for each temperature was further calculated from the slopes of respective graphs using following equation (8) :
The drug concentration in the T3 samples and the data for calculation of shelf-life of samples kept in plastic containers are shown in Tables VIII and IX. The shelf-life of the samples kept in plastic containers was calculated using the value of K at 25°C (K 25 ). The shelf-life of optimized palm olein-based betamethasone 17-valerate emulsions stored in plastic containers was found to be 2 years.
CONCLUSION
The findings suggested that betamethasone 17-valerate is compatible with palm olein emulsion as the physicochemical characteristics of the control and test emulsions were not significantly different. Higher drug release rate of betamethasone 17-valerate from palm olein emulsion into cellulose acetate membrane was observed. Further, the amount of drug deposited in rat skin with test sample, T1, was approximately four times higher than commercial samples, R2 and R3. The biotransformation of betamethasone 17-valerate by rat skin enzymes can be used as a prodrug approach to achieve synergistic action in patients with deeper skin manifestations. Maximum degradation of betamethasone 17-valerate observed after 3 months was less than 4% when kept at 40°C. According to ICH guidelines, all test samples passed since less than 5% of the drug molecule was found to degrade throughout the study period. It was also proven that the formulations were compatible with the chosen container and closuresystembasedontheretentionofphysicochemicalproperties throughout the period of study. In conclusion, palm olein can be used as the oil phase for topical delivery of lipophilic drug.
